

# ANNUAL FINANCIAL STATEMENTS

84

---

BALANCE SHEET AS OF  
31 DECEMBER 2019

86

---

STATEMENT OF  
PROFIT AND LOSS  
FOR THE 2019  
FINANCIAL YEAR

88

---

NOTES TO THE  
FINANCIAL STATEMENTS  
FOR THE 2019  
FINANCIAL YEAR

120

---

INDEPENDENT  
AUDITOR'S REPORT

Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin

**BALANCE SHEET AS OF 31 DECEMBER 2019**

ASSETS	EUR	EUR	EUR	31.12.2019 EUR	31.12.2018 TEUR
<b>A. Fixed assets</b>					
<b>I. Intangible assets</b>					
1. Purchased concessions, industrial property rights and similar rights and assets, as well as licences to such rights and assets		12,115,640.41			12,801
2. Prepayments made		1,373,393.93			1,015
			13,489,034.34		13,816
<b>II. Tangible fixed assets</b>					
1. Land, rights equivalent to land, and buildings including buildings on third-party land		1,227,282,740.06			1,267,745
2. Technical plant and machinery		492,702,094.79			528,305
3. Other plant, operating and office equipment		196,998,898.52			216,904
4. Prepayments made and plant under construction		251,730,091.87			177,671
			2,168,713,825.24		2,190,625
<b>III. Financial assets</b>					
1. Shares in affiliated companies		595,200.00			595
2. Participations		288,076.97			288
3. Investment securities		131,884,024.98			129,785
4. Other loans and shares		1,866,291.41			2,694
			134,633,593.36		133,362
			2,316,836,452.94		2,337,803
<b>B. Current assets</b>					
<b>I. Inventories</b>					
1. Research materials		10,194,350.50			10,008
2. Other materials		1,042,617.25			1,109
3. Work-in-progress		967.00			1
			11,237,934.75		11,118
<b>II. Receivables and other assets</b>					
1. Trade receivables		8,028,351.31			8,700
2. Receivables due from funding providers					
a) from institutional funding	103,802,729.92				127,356
b) from project funding	31,840,594.64				31,539
c) from compensation claims	714,760,987.80				629,354
			850,404,312.36		788,249
3. Receivables due from affiliated companies		36,157,456.86			7,811
4. Receivables due from companies in which an equity interest is held		1,153.14			37
5. Other assets		26,492,708.48			20,545
			921,083,982.15		825,342
<b>III. Securities</b>					
Shares in affiliated companies			27,000.00		27
<b>IV. Cash in hand, bank balances and cheques</b>					
			121,043,913.52		142,533
				1,053,392,830.42	979,020
<b>C. Deferred expenses and accrued income</b>					
				36,582,628.25	36,062
<b>TOTAL</b>					
				<b>3,406,811,911.61</b>	<b>3,352,885</b>
<i>for information purposes:</i>					
Trust assets				126,645,362.14	113,934

**EQUITY AND LIABILITIES**

	EUR	EUR	EUR	31.12.2019 EUR	31.12.2018 TEUR
<b>A. Equity</b>					
I. Association capital			152,651,684.86		145,166
II. Reserves for statutory purposes			24,908,232.89		24,414
III. Result carried forward			2,562,023.04		1,245
				180,121,940.79	170,825
<b>B. Extraordinary item</b>					
1. From subsidies for fixed assets			2,156,279,707.59		2,178,460
2. From subsidies for current assets			79,662,892.97		56,155
				2,235,942,600.56	2,234,615
<b>C. Provisions</b>					
1. Provisions for pensions and similar obligations			600,818,964.00		536,697
2. Tax provisions			0.00		0
3. Other provisions			108,272,616.82		87,993
				709,091,580.82	624,690
<b>D. Liabilities</b>					
1. Bank borrowings			566,105.34		582
2. Trade payables			55,985,595.09		54,613
3. Liabilities to funding providers					
a) from institutional funding		114,123,200.40			159,832
b) from project funding		84,673,212.86			75,047
			198,796,413.26		234,879
4. Liabilities due to affiliated companies			2,125,000.00		8,900
5. Liabilities due to companies in which an equity interest is held			20,847.76		22
6. Other liabilities			22,281,803.77		21,670
– of which from tax:		12,674,049.81			
		(31.12.2018: 11,682,682.58)			
– of which as part of social security:		2,329,099.27			
		(31.12.2018: 2,072,389.53)			
				279,775,765.22	320,666
<b>E. Deferred income and accrued expenses</b>				1,880,024.22	2,089

<b>TOTAL</b>				<b>3,406,811,911.61</b>	<b>3,352,885</b>
--------------	--	--	--	-------------------------	------------------

for information purposes:  
Trust liability

126,645,362.14      113,934

Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin

# STATEMENT OF PROFIT AND LOSS FOR THE 2019 FINANCIAL YEAR

	EUR	EUR	2019 EUR	Previous year TEUR
<b>1. Subsidies from institutional funding</b>				
1.1 Basic funding		1,839,887,698.11		1,785,329
1.2 Partial special funding		17,200,000.00		14,448
1.3 Special funding		6,140,106.62		3,814
1.4 Other partial special funding		1,841,840.00		1,804
			1,865,069,644.73	1,805,395
<b>2. Changes in receivables due from funding providers deriving from compensation claims (increase /(-) decrease)</b>			85,406,566.12	55,374
<b>3. Own revenues and other income</b>				
3.1 Income from research and development and from utilization of research facilities		2,749,457.22		2,072
3.2 Income from licence and know-how agreements		20,032,067.87		29,441
3.3 Income from infrastructure services and sales of materials		21,280,866.77		21,468
3.4 Rental and lease income		16,077,169.25		15,321
3.5 Income from fixed asset disposals		4,685,510.90		7,234
3.6 Increase /(-) decrease in work-in-progress		0.00		-2
3.7 Other work performed by the enterprise and capitalized		7,600,901.46		7,647
3.8 Financial income, income from participating interests, interest income		5,449,095.06		5,015
3.9 Other operating income		218,810,339.64		191,678
			296,685,408.17	279,874
<b>4. Subsidies from project funds</b>			249,527,506.94	246,777
<b>5. Income from the release of extraordinary items (loan repayment)</b>			1,104,659.55	1,151
carried forward			2,497,793,785.51	2,388,571

	EUR	EUR	2019 EUR	Previous year TEUR
carried forward			2,497,793,785.51	2,388,571
<b>6. Personnel expenses</b>				
6.1 Wages and salaries		972,496,429.85		919,165
6.2 Social security contributions and expenses for pensions and benefits		302,229,289.39		261,628
– of which for pensions:	107,510,910.56 (previous year: 78,731,813.84)		1,274,725,719.24	1,180,793
<b>7. Costs of materials</b>				
7.1 Expenses for raw materials, consumables and supplies, and for purchased goods		194,172,957.24		193,100
7.2 Expenses for purchased services		12,324,269.80		10,471
			206,497,227.04	203,571
<b>8. Change in the extraordinary item for current assets (increase /(-) decrease)</b>				
			23,296,755.70	-6,221
<b>9. Depreciation and amortization of intangible and tangible fixed assets</b>				
9.1 Depreciation and amortization of intangible and tangible fixed assets		358,496,019.16		361,273
9.2 Income from release due to amortization and depreciation of extraordinary items for intangible and tangible fixed assets		357,227,596.26		360,292
			1,268,422.90	981
<b>10. Other expenses</b>				
10.1 Interest and similar expenses		16,192,847.73		17,195
– of which from the reversal of discounts to provisions:	16,189,955.38 (previous year: 17,192,093.57)			
10.2 Other operating expenses		585,405,556.37		624,320
			601,598,404.10	641,515
<b>11. Transfers and subsidies granted</b>				
			40,279,414.38	41,585
<b>12. Expenses from addition to the extraordinary item (subsidized investments)</b>				
12.1 to finance intangible and tangible fixed assets		340,617,158.45		321,984
12.2 to finance financial assets and shares in spin-offs		213,951.06		1,451
			340,831,109.51	323,435
<b>13. Annual result</b>				
			<b>9,296,732.64</b>	<b>2,912</b>
<b>14. Result carried forward from the previous year</b>				
			1,244,600.49	1,710
<b>15. Withdrawals from the association capital</b>				
			991,415.88	453
<b>16. Withdrawals from reserves for statutory purposes</b>				
			1,943,968.02	2,871
<b>17. Allocations to association capital</b>				
			-8,476,401.89	-1,712
<b>18. Allocations to reserves for statutory purposes</b>				
			-2,438,292.10	-4,989
<b>19. Result carried forward</b>				
			<b>2,562,023.04</b>	<b>1,245</b>

Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin

# NOTES TO THE FINANCIAL STATEMENTS FOR THE 2019 FINANCIAL YEAR

of the Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin  
Register of Societies No. 13378 B, Berlin-Charlottenburg District Court


## 1. General information on the Annual Financial Statements

The annual financial statements of the Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (hereafter "MPG") were prepared in analogous application of the regulations of the Third Book of the German Commercial Code (HGB) for large corporations with due consideration given to association law.

The annual financial statements of MPG include the following accounting entities:

- Legally dependent Institutes and research units as well as central institutions
- "Assets not publicly funded" (hereafter NÖV)
- Operations pursuant to § 26 of the Federal Budget Ordinance (BHO) (including the MPI for Psychiatry)
- Max Planck Institute for Plasma Physics (hereafter IPP)

Together with the legally independent Max Planck Institutes (the Max-Planck-Institut für Eisenforschung Gesellschaft mit beschränkter Haftung and the Max-Planck-Institut für Kohlenforschung (rechtsfähige Stiftung)), the MPG excluding IPP forms a consortium of applicants which is the recipient of joint institutional funding from the federal administration and federal states. The annual financial statements of the legally independent Institutes are not included in the annual financial statements of the MPG.



The "assets not publicly funded" represent assets belonging to the MPG made up of private third-party funds which are managed with due regard for intended purpose, tax regulations and public funding law. The MPG generates income from these assets, which is used for the promotion of research. In the explanations on individual items on the assets side of the balance sheet, the share of assets not publicly funded is identified by applying a further breakdown of figures.

Advantage was taken of the options afforded under § 265 paras. 5 to 7 HGB in order to reflect the particularities specific to the sector and legal form of MPG as a research facility, and to ensure a clear, transparent presentation. On the one hand, the designation and structure of the items of the balance sheet and of the statement of profit and loss were adjusted, and on the other, items in the profit and loss account were combined. In accordance with the budget of the MPG, scholarships for supported junior personnel are shown under personnel expenses.

## 2. Accounting Policies

---

Intangible and tangible fixed assets are measured at their costs of purchasing or manufacturing on the date of addition. For subsequent valuation, they are amortized and depreciated exclusively applying the straight-line method. For this purpose, the MPG applies a generalized useful life specific to asset class.

Low-value assets with costs of purchasing and manufacturing up to EUR 800 (net) inclusive are fully expensed in special accounts in the year of purchase.

Financial assets are recognized at purchase cost. Financial assets are written down to the lower of cost or fair value given prospectively permanent impairment.

The research materials shown under inventories and other materials are recognized at the lower of cost or fair value.

Work-in-progress includes work conducted by IPP – measured on the basis of unit costings - which, as well as directly attributable costs of materials, wage costs and special costs, also including appropriate portions of production and materials overheads as well as the asset erosion of the utilized fixed assets.

Receivables and other assets are recognized at the lower of nominal or fair value. No generalized valuation allowances have been applied due to the minor portfolio of receivables, which is generally to be regarded as collectible.

Liquid funds are measured at nominal value.

Current bank balances denominated in foreign currencies were translated at the spot mid exchange rate on the balance sheet date in accordance with § 256 a HGB.

Accruals and deferrals are formed in accordance with the principles of periodic allocation.

Equity is reported based on the IDW accounting standard "Accounting for associations" (IDW RS HFA 14).

The MPG receives funding from the public sector and other third parties. Where these have been used for the purchase or production of fixed assets requiring capitalization, they have been recognized as liabilities in the form of an extraordinary item from subsidies for fixed assets, and are not offset with costs of purchasing or manufacturing (gross method). This does not apply to assets of the NÖV.

Similarly, the extraordinary item from subsidies for current assets reflects the current assets financed through institutional or project funding.



Provisions are formed for all identifiable risks and contingent obligations, taking due account of the probable utilization at the settlement amount required on the basis of prudent commercial judgement. Future increases in prices and costs are taken into account if sufficient objective indications exist that they will occur. Provisions are discounted in accordance with § 253 para. 2 HGB if their residual term is more than one year, in other words, applying the average market interest rate corresponding to the residual term, derived in the case of pension provisions over the past ten financial years, and in the case of other provisions from the past seven financial years. Income or expenses resulting from changes in the discount rate, or the interest effects of a change in the estimate of the residual term, are shown in personnel expenses or in other operating expenses, depending on the provision type.

Pension provisions have been calculated based on an independent actuarial report in accordance with the accrued funding method, taking into account the 2018 G Mortality Tables of Prof. Dr. Heubeck. A trend of 1.50% (previous year 1.50%) was assumed for both salaries and pensions. The average market interest rate for the past ten years of 2.71% (previous year 3.21%) was applied for the discounting for a generalized residual term of 15 years. The discounting applying the average market interest rate for the past ten years generates a difference of EUR 53,345,376 (previous year 56,339,369) compared with discounting applying the average market rate for the past seven years (1.97%).

Provisions for aid obligations have been calculated based on an independent actuarial report in accordance with the accrued funding method, taking into account the current probability tables (average insurance payout statistics [Kopfschadenstatistiken]) in private health insurance for 2018, as published by the German Federal Financial Supervisory Authority (BaFin), as well as the 2018 G Mortality Tables of Prof. Dr. Heubeck. This entailed taking as a basis an average market interest rate for the past seven years of 1.97% (previous year 2.32%) for a generalized residual term of 15 years and a benefit trend of 2.00% (previous year 2.00%).

The partial retirement provision was determined by means of an independent actuarial report taking into account the 2018 G Mortality Tables of Prof. Dr. Heubeck. As well as settlement arrears, the calculation includes the complete amounts above the current salary in existing partial retirement arrangements. The calculation was based on an average market interest rate from the last seven years of 0.63% corresponding to the residual term (previous year 0.87%), 0.84% for IPP (previous year 1.11%) as well as a salary trend of 1.50% (previous year 1.50%).

The anniversary obligation provision was determined by means of an independent actuarial report based on the projected unit credit method taking into account the 2018 Mortality Tables of Prof. Dr. Heubeck, an actuarial interest rate of 1.97% (previous year 2.32%) for a generalized residual term of 15 years, and a salary trend of 1.50% (previous year 1.50%).

Liabilities are recognized at their settlement amount.

Receivables and liabilities denominated in foreign currencies are translated on the balance sheet date at the spot mid exchange rate.

Trust assets essentially comprise trust-administered EU project funds. They are matched by corresponding trust liabilities.

The statement of profit and loss is complemented by a statement showing the application of results.

### 3. Explanations and notes to the balance sheet

#### 3.1 Fixed assets

Changes in individual items of fixed assets are shown in the annex to the notes to the financial statements in the statement of changes in fixed assets.

#### Intangible assets

	31.12.2019 TEUR	of which NÖV	31.12.2018 TEUR
<b>INTANGIBLE ASSETS</b>			
Purchased concessions, industrial property rights and similar rights and assets, as well as licences to such rights and assets	12,116	19	12,801
Prepayments made	1,373	0	1,015
<b>TOTAL</b>	<b>13,489</b>	<b>19</b>	<b>13,816</b>

Intangible assets essentially comprise software licences.

The MPG does not make use of the capitalization option for internally generated intangible assets pursuant to § 248 para. 2 HGB.

#### Tangible fixed assets

	31.12.2019 TEUR	of which NÖV	31.12.2018 TEUR
<b>TANGIBLE FIXED ASSETS</b>			
Land, rights equivalent to land, and buildings including buildings on third-party land	1,227,283	24,598	1,267,745
Technical plant and machinery	492,702	0	528,305
Other plant, operating and office equipment	196,999	1,407	216,904
Prepayments made and plant under construction	251,730	45	177,671
<b>TOTAL</b>	<b>2,168,714</b>	<b>26,050</b>	<b>2,190,625</b>

The reduction in **land, rights equivalent to land, and buildings including buildings on third-party land** is due to the fact that the depreciation and amortization in the reporting year exceeded the capitalization of construction projects after completion. The following large-scale construction project was capitalized in the reporting year after completion:

	TEUR
MPI of Molecular Plant Physiology, Potsdam, new Institute building 2nd constr. phase	18,818

The item **technical plant and machinery** comprises essentially the scientific equipment and devices as well as operating facilities (mainly fixed installations in laboratories, animal facilities and greenhouses), produced as part of the construction projects.

The item **other plant, operating and office equipment** is comprised as follows on the balance sheet date:

	31.12.2019 TEUR	31.12.2018 TEUR
<b>Other plant, operating and office equipment</b>		
Facility and IT equipment	154,042	173,474
Libraries	41,379	42,000
Vehicles	1,578	1,430
<b>TOTAL</b>	<b>196,999</b>	<b>216,904</b>

The increase in **prepayments made and plant under construction** is essentially the result of expenditure for construction projects before completion.

## Financial assets

	31.12.2019 TEUR	<i>of which NÖV</i>	31.12.2018 TEUR
<b>FINANCIAL ASSETS</b>			
Shares in affiliated companies	595	526	595
Participations	288	238	288
Investment securities	131,884	131,884	129,785
Other loans and shares	1,866	1,210	2,694
<b>TOTAL</b>	<b>134,633</b>	<b>133,858</b>	<b>133,362</b>

There were no indications of prospectively permanent impairment as of the balance sheet date.

The reported participations serve the MPG as part of its statutory purpose to establish long-term science-driven cooperation.

**Other loans and shares** contain loans for housebuilding funding (family home loans) amounting to TEUR 1,841 as well as other loans (TEUR 25).

An overview of shareholdings can be found in note 5 Other disclosures of these notes to the financial statements.

## 3.2 Current assets

### Inventories

Inventories comprise assets which are not serving operations on a continuing basis and are purchased for consumption. As the MPG conducts basic research, instead of the raw materials, consumables and supplies closely associated with production manufacturing, the materials required for research are reported and divided as follows within inventories:

	31.12.2019 TEUR	of which NÖV	31.12.2018 TEUR
<b>INVENTORIES</b>			
Research materials	10,194	0	10,008
Other materials	1,043	39	1,109
Work-in-progress	1	0	1
<b>TOTAL</b>	<b>11,238</b>	<b>39</b>	<b>11,118</b>

### Receivables and other assets

	31.12.2019 TEUR	of which NÖV	31.12.2018 TEUR
<b>RECEIVABLES AND OTHER ASSETS</b>			
Trade receivables	8,028	83	8,700
Receivables due from funding providers	850,404	0	788,249
Receivables due from affiliated companies	36,158	0	7,811
Receivables due from companies in which an equity interest is held	1	0	37
Other assets	26,493	16,971	20,545
<b>TOTAL</b>	<b>921,084</b>	<b>17,054</b>	<b>825,342</b>

**Trade receivables** relate in an amount of TEUR 5,671 (31 December 2018: TEUR 5,576) to receivables from hospital services of the MPI for Psychiatry.

	31.12.2019 TEUR	31.12.2018 TEUR
<b>Receivables due from funding providers</b>		
from institutional funding	103,803	127,356
from project funding	31,840	31,539
from compensation claims	714,761	629,354
<b>TOTAL</b>	<b>850,404</b>	<b>788,249</b>

**Receivables due from funding providers from institutional funding** essentially represent receivables for approved funding in the reporting year whose multi-year availability is established by the budget instrument of funds managed under own responsibility (Selbstbewirtschaftung). In relation to accounts managed under own responsibility for the federal administration and its federal states, an amount of TEUR 92,262, of which TEUR 5,226 for IPP (previous year TEUR 114,909, of which TEUR 4,720 for IPP), was held as of the reporting date. Also shown here are claims to additional payments from federal states resulting from the final calculation by the MPG of fund distribution, which in principle are to be paid in the third year following billing (TEUR 11,541); of this amount, TEUR 5,215 (previous year TEUR 6,326) has a residual term of over one year.

**Receivables due from funding providers from project funding** include project funding expenditure covered by funding approval letters from third-party funding bodies if the third-party funds have not yet been received.

**Receivables due from funding providers from compensation claims** form the counterpart, in principle, to obligations entered into on the basis of a funding relationship and not covered by funds in the current financial year (No. 4 (2) of the Management Principles for the MPG (BewGr-MPG)). They are comprised as follows as on the reporting date:

	TEUR
MPG excluding IPP	679,774
IPP	34,987

The compensation receivable for the MPG excluding IPP corresponds to the level of the provisions (excluding NÖV). Due to the fact that it belongs to the Helmholtz Association, IPP's compensation receivable is recognized in accordance with the special accounting rules in place for member institutions of the Helmholtz Association.

Of the compensation claims, a total of TEUR 611,678 (previous year TEUR 546,448) have a residual term of over one year.

**Receivables due from affiliated companies** relate mainly to receivables due from Max-Planck-Innovation GmbH deriving from licence income and from a loan granted to MPDL Services GmbH.

As of the balance sheet date, **other assets** include:

	TEUR
Claims from legacies (NÖV)	14,612
VAT receivables due from tax authorities	3,208
Receivables from investment securities (NÖV)	1,569
Shares in spin-offs held-for-disposal	1,171

Spin-offs are companies established to convert a technology or scientific know-how developed at a Max Planck Institute into products and services, among other objectives. Equity interests in spin-offs are held on the basis of guidelines for research facilities to participate in spin-offs for the purpose of the transfer of knowledge and technology published by the Federal Ministry of Education and Research.

The shares in spin-offs held for sale were written down in the reporting year to their lower of cost or fair value of TEUR 3.

## Securities

	31.12.2019 TEUR	<i>of which NÖV</i>	31.12.2018 TEUR
<b>SECURITIES</b>			
Shares in affiliated companies	27	0	27

The shares in affiliated companies are held for the MPDL Services GmbH, München.

## Cash in hand, bank balances and cheques

	31.12.2019 TEUR	<i>of which NÖV</i>	31.12.2018 TEUR
Cash in hand, bank balances and cheques	121,044	4,259	142,533

As of the reporting date, the liquid funds position contains unutilized budget funds from institutional funding whose multi-year availability is established by other budget instruments outside of funds managed under own responsibility (Selbstbewirtschaftung), as well as funds from project funding which can also be transferred to the following year.

## 3.3 Deferred expenses and accrued income

	31.12.2019 TEUR	<i>of which NÖV</i>	31.12.2018 TEUR
Deferred expenses and accrued income	36,583	14	36,062

Deferred expenses and accrued income contain expenditure before the balance sheet date which will only be recognized after that date. This item mainly contains prepayments of licensing fees and usage fees for (online) media. Salary payments of TEUR 6,776 for January 2020 are included, which are due on 1 January 2020.

## 3.4 Trust assets

The trust assets include TEUR 125,475 of trust-administered EU project funds, of which TEUR 74,972 are attributable to IPP.

### 3.5 Equity

	31.12.2019 TEUR	31.12.2018 TEUR
<b>EQUITY</b>		
Association capital	152,652	145,166
Reserves for statutory purposes	24,908	24,414
Result carried forward	2,562	1,245
<b>TOTAL</b>	<b>180,122</b>	<b>170,825</b>

Equity is entirely accounted for by NÖV. Equity is reported with due consideration given to funding provider requirements and reflecting tax law regulations. Regarding the reserves, the specifications contained in the regulations of the German Fiscal Code (AO) have been implemented. The equity has increased by the annual result of TEUR 9,297.

Apart from NÖV, the annual financial statements of the MPG close without net profit or net loss for the year.

### 3.6 Extraordinary item

The extraordinary item is comprised as follows:

	31.12.2019 TEUR	31.12.2018 TEUR
<b>EXTRAORDINARY ITEM</b>		
from subsidies for fixed assets	2,156,280	2,178,460
from subsidies for current assets	79,663	56,155
<b>TOTAL</b>	<b>2,235,943</b>	<b>2,234,615</b>

The **extraordinary item from subsidies for fixed assets** reflects the fixed assets funded by public sector subsidies and subsidies from other third parties. Accordingly, no extraordinary item was formed for NÖV fixed assets and for an inheritable building right at the MPI for Psychiatry (TEUR 629), which is matched by a long-term liability. This results in the following table of extraordinary items and fixed assets as of the closing date:

	Fixed assets covered by extraordinary items	Fixed assets not covered by extraordinary items		Total fixed assets
	TEUR	NÖV TEUR	MPI for Psychiatry TEUR	TEUR
Intangible assets	13,470	19	0	13,489
Tangible fixed assets	2,142,035	26,050	629	2,168,714
Financial assets	775	133,858	0	134,633
<b>TOTAL</b>	<b>2,156,280</b>	<b>159,927</b>	<b>629</b>	<b>2,316,836</b>

The **extraordinary item from subsidies for current assets** reflects the current assets financed through institutional or project funding.

## 3.7 Provisions

**Provisions for pensions and similar obligations** are comprised as follows:

	1.1.2019 TEUR	Consumption TEUR	Release TEUR	Reversal of discount TEUR	Addition TEUR	31.12.2019 TEUR
Pension obligations	447,395	- 19,452	- 9,468	14,049	65,011	497,535
Aid obligations	89,302	- 3,014	- 2,249	2,037	17,208	103,284
<b>TOTAL</b>	<b>536,697</b>	<b>- 22,466</b>	<b>- 11,717</b>	<b>16,086</b>	<b>82,219</b>	<b>600,819</b>

Provisions for pensions and similar obligations are formed for benefit claims and entitlements for aid resulting from employment contracts similar to civil service contracts which may be concluded under the conditions pertaining to the Annex to No. 8 (1) Bew-Gr-MPG. A total of 1,293 (previous year 1,282) entitled persons, of whom 663 active (previous year 660), are included in the provision for pension obligations as of the reporting date, and a total of 890 (previous year 887) entitled persons, of whom 456 active (previous year 464), are included in the provision for aid obligations. The interest expense shown derives from reversing the discount to the obligation at the beginning of the period applying the interest rate defined at this time, taking into consideration the interest portion of the pensions or aid paid to the beneficiaries in the reporting year. The increase in provisions for pensions and similar obligations results principally from the reduction in the actuarial interest rate on which the calculation is to be based, pursuant to § 253 para. 2 HGB.

The difference between discounting applying the average market interest rate for the past ten years and discounting applying the average market interest rate for the past seven years amounts to TEUR 53,345 (previous year TEUR 56,339) for the provisions for pension obligations as of the reporting date.

The formation of **tax provisions** was not required as of the balance sheet date.

**Other provisions** are comprised as follows:

	1.1.2019 TEUR	Consumption TEUR	Release TEUR	Reversal of discount TEUR	Addition TEUR	31.12.2019 TEUR
Remaining vacation	42,389	- 42,389	0	0	57,777	57,777
Invoices outstanding	20,846	- 20,846	0	0	24,322	24,322
Partial retirement	4,951	- 2,467	0	42	3,058	5,584
Overtime/time credits	5,573	- 2,894	0	0	3,526	6,205
Travel costs not yet invoiced	2,922	- 2,707	0	0	2,231	2,446
Archiving costs	2,763	0	0	0	237	3,000
Service anniversaries	2,037	- 129	0	41	326	2,275
Legal costs	2,087	- 26	- 611	0	322	1,772
Miscellaneous other provisions	4,425	- 1,846	- 535	21	2,826	4,891
<b>TOTAL</b>	<b>87,993</b>	<b>- 73,304</b>	<b>- 1,146</b>	<b>104</b>	<b>94,625</b>	<b>108,272</b>

Besides short-term flexi-time credits, provisions for overtime/time credits also include longer-term working time accounts in an amount of TEUR 2,692.



## 3.8 Liabilities

	31.12.2019 TEUR	31.12.2018 TEUR
<b>LIABILITIES</b>		
Bank borrowings	566	582
Trade payables	55,986	54,613
Liabilities to funding providers	198,796	234,879
Liabilities due to affiliated companies	2,125	8,900
Liabilities due to companies in which an equity interest is held	21	22
Other liabilities	22,282	21,670
<b>TOTAL</b>	<b>279,776</b>	<b>320,666</b>

**Bank borrowings** relate entirely to NÖV.

**Trade payables** mainly contain typical liabilities from supplies and services. They also include warranty retentions of TEUR 681 (previous year TEUR 668).

	31.12.2019 TEUR	31.12.2018 TEUR
<b>Liabilities to funding providers</b>		
from institutional funding	114,123	159,832
from project funding	84,673	75,047
<b>TOTAL</b>	<b>198,796</b>	<b>234,879</b>

Pursuant to No. 5 of the Management Principles for the MPG (BewGr-MPG), the multi-year availability of funding from institutional funding providers can be established by means of funds managed under own responsibility (Selbstbewirtschaftung) or by another budget instrument. These multi-year available funds are shown on the balance sheet as **liabilities to funding providers from institutional funding**. The balance of approved subsidies, own revenues and other income as well as expenditure in the reporting year is shown. The decrease reflects the reduction in multi-year available funds.

Also shown here are TEUR 17,076 of reimbursement claims of federal states resulting from the MPG's final calculation of fund distribution which in principle are to be paid in the third year following billing; TEUR 7,482 of this amount has a residual term of over one year.

**Liabilities to funding providers from project funding** essentially contain the funds available for the following year as the balance of third-party funding subsidies received, own revenues and other income, and expenses in the reporting year.

**Liabilities due to affiliated companies** relate to the Max-Planck-Institut für Eisenforschung GmbH in the framework of funding not yet called off as part of the consortium of applicants in 2019.

**Other liabilities** contain liabilities towards tax authorities resulting from income tax in the amount of TEUR 12,674 as of the balance sheet date.

The following **statement of liabilities** shows the residual terms of individual liability items (previous-year data in parentheses):

	Residual term			
	31.12.2019 TEUR	up to 1 year TEUR	1 to 5 years TEUR	more than 5 years TEUR
<b>STATEMENT OF LIABILITIES</b>				
Bank borrowings	566 (582)	17 (16)	67 (67)	482 (499)
Trade payables	55,986 (54,613)	55,986 (54,592)	0 (21)	0 (0)
Liabilities to funding providers	198,796 (234,879)	191,314 (225,285)	7,482 (9,594)	0 (0)
Liabilities due to affiliated companies	2,125 (8,900)	2,125 (8,900)	0 (0)	0 (0)
Liabilities due to companies in which an equity interest is held	21 (22)	21 (22)	0 (0)	0 (0)
Other liabilities	22,282 (21,670)	21,676 (20,979)	332 (301)	274 (390)
<b>TOTAL</b>	<b>279,776</b> <b>(320,666)</b>	<b>271,197</b> <b>(309,794)</b>	<b>7,823</b> <b>(9,983)</b>	<b>756</b> <b>(889)</b>

The liabilities are not secured through rights of lien or similar rights.

### 3.9 Deferred income and accrued expenses

	31.12.2019 TEUR	31.12.2018 TEUR
Deferred income and accrued expenses	1,880	2,089

Deferred income and accrued expenses contains revenues received before the balance sheet date which will only be recognized in profit or loss after that date. A total of TEUR 1,565 of the deferred income and accrued expenses is attributable to the IPP.

## 4. Explanations to the statement of profit and loss

### Subsidies from institutional funding

The subsidies from institutional funding TEUR 1,865,070 (previous year TEUR 1,805,395) are comprised as follows in the reporting year:

	2019 MPG excl. IPP TEUR	2019 IPP TEUR	2019 MPG TEUR	2018 MPG TEUR
<b>SUBSIDIES FROM INSTITUTIONAL FUNDING</b>				
Basic funding	1,728,488	111,400	1,839,888	1,785,329
<i>of which from federal government</i>	960,610	100,552	1,061,162	1,007,232
<i>of which from federal states</i>	767,878	10,848	778,726	778,097
Partial special funding	17,200	0	17,200	14,448
<i>of which from federal government</i>	0	0	0	0
<i>of which from federal states</i>	17,200	0	17,200	14,448
Special funding	6,140	0	6,140	3,814
<i>of which from federal government</i>	0	0	0	0
<i>of which from federal states</i>	6,140	0	6,140	3,814
Other partial special funding	1,842	0	1,842	1,804
<b>TOTAL</b>	<b>1,753,670</b>	<b>111,400</b>	<b>1,865,070</b>	<b>1,805,395</b>

The federal government and the federal states provide on a 50:50 basis the financial funding in the **basic funding** of the MPG excluding IPP. This increased by 3% in 2019 in accordance with the agreement of the Joint Initiative for Research and Innovation III. The federal government bore this rise alone, also in accordance with the Joint Initiative agreement.

**Other partial special funding** relates to a subsidy from the Netherlands for the MPI for Psycholinguistics, Nijmegen.

### Changes in receivables due from funding providers deriving from compensation claims

The change in receivables due from funding providers deriving from compensation claims of TEUR 85,407 (previous year TEUR 55,374) is comprised as follows:

	2019 TEUR	2018 TEUR
MPG excluding IPP	81,127	55,002
IPP	4,280	372

With reference to MPG excluding IPP this item results from changes to provisions (excluding NÖV).

## Own revenues and other income

Own revenues and other income of TEUR 296,685 (previous year TEUR 279,874) are comprised as follows:

	2019 TEUR	2018 TEUR
<b>OWN REVENUES AND OTHER INCOME</b>		
Income from research and development, and from utilization of research facilities	2,749	2,072
Income from licence and know-how agreements	20,032	29,441
Income from infrastructure services and sales of materials	21,281	21,468
Rental and lease income	16,077	15,321
Income from fixed asset disposals	4,686	7,234
Increase /(-) decrease in work-in-progress	0	-2
Other work performed by the enterprise and capitalized	7,601	7,647
Financial income, income from participating interests, interest income	5,449	5,015
Other operating income	218,810	191,678
<i>containing</i>		
Income relating to another accounting period	1,419	2,797
Other income	37,517	29,724
Release of multi-year available funds	179,874	159,157

**Income from licence and know-how agreements** originated from the utilization of the MPG's intangible invention assets by Max-Planck-Innovation GmbH and from the disposal of shares in technology transfer spin-offs. The reduction is primarily due to a particular effect resulting from the first-time accounting of an estimated revenue in the previous year. In addition to the income received up to the preparation of the financial statements, the income includes forecast income in the amount of TEUR 9,529 (previous year TEUR 7,289) that is attributable to the financial year but will only be received in the course of the following year.

**Income from infrastructure services and sales of materials** consists mainly of revenues generated by the MPI for Psychiatry from hospital services.

**Rental and lease income** results mainly from letting guest apartments and guest rooms. It also contains NÖV income (including the conference venues Schloss Ringberg and Harnack-Haus) in the amount of TEUR 4,897 (previous year TEUR 4,377).

**Expenditure arising from the disposal of fixed assets** (for subsidy-financed fixed assets) is offset by the same amount of income resulting from the release of the extraordinary item from subsidies for fixed assets, and is shown in income from fixed asset disposals.

Of the **other work performed by the enterprise and capitalized** an amount of TEUR 4,394 is attributable to the IPP (previous year: TEUR 4,818).

**Financial income, income from participating interests, interest income** contains income from securities recognized in NÖV, amounting to TEUR 4,269 (previous year TEUR 4,834).

**Income relating to another accounting period** includes income from subsequent capitalizations in an amount of TEUR 365.

**Other income** contains income from the release of provisions amounting to TEUR 12,863 (previous year TEUR 9,161).

Multi-year available funds from institutional funding as well as from project funding in the current year are expensed as a liability to funding providers, and released in the following year as income in the same amount. The **release of multi-year available funds** (from 2018) relates only to MPG excluding IPP, and is comprised as follows:

	TEUR
<b>Release of multi-year available funds</b>	
Basic funding	131,875
Special funding	2,582
Project funding	41,927
Undisbursed funds for operations pursuant to § 26 of the Federal Budget Ordinance (BHO) including MPI for Psychiatry	3,490
<b>TOTAL</b>	<b>179,874</b>

## Subsidies from project funds

IPP accounts for TEUR 22,813 (previous year TEUR 30,848) of the TEUR 249,528 subsidies from project funds (previous year TEUR 246,777).

## Income from the release of extraordinary items (loan repayment)

This item (TEUR 1,105, previous year TEUR 1,151) contains the income from the release of the extraordinary item from subsidies for fixed assets arising from redemption payment of family home loans.

## Personnel expenses

Personnel expenses contain expenses for the support of junior scientists amounting to TEUR 302,295 (previous year 255,566 TEUR). Scholarship holders account for TEUR 19,267 (previous year TEUR 25,648). The continuing reduction in 2019 in expenses for scholarship holders arises from the realignment of funding structures for junior scientists in the MPG, which was started in mid-2015, and the related conversion of scholarships to funding contracts.

**Social security contributions and expenses for pensions and benefits** (TEUR 302,229, previous year TEUR 261,628) includes the balance from the addition to, and consumption of, provisions for pension obligations in an amount of TEUR 45,559 (previous year TEUR 24,646) and for aid obligations in an amount of TEUR 14,194 (previous year TEUR 11,157). Expenses for aid payments were incurred in a total of TEUR 4,825 (previous year TEUR 4,398) and for childcare costs in an amount of TEUR 2,139 (previous year TEUR 1,313).

## Costs of materials

**Expenses for raw materials, consumables and supplies, and for purchased goods** (TEUR 194,173, previous year TEUR 193,100) mainly contain expenses for research materials of TEUR 109,003 (previous year TEUR 108,188) and expenses for power and water supplies amounting to TEUR 81,842 (previous year TEUR 81,043).

**Expenses for purchased services** of TEUR 12,324 (previous year TEUR 10,471) chiefly represent expenses for awarding external research contracts in the area of third-party funding.

## Change in the extraordinary item for current assets

The increase in the extraordinary item for current assets in an amount of TEUR 23,297 is composed of:

- the increase in the extraordinary item recognized on the balance sheet for current assets (TEUR 23,508),
- less the changes to shares in spin-offs held for disposal (TEUR 211).

## Depreciation and amortization of intangible and tangible fixed assets

Since fixed assets are shown by the gross method, which necessitates showing depreciation and amortization as an expense item in the statement of profit and loss, an amount corresponding to the depreciation and amortization (TEUR 358,496, previous year TEUR 361,273) is released from the extraordinary item of subsidies to fixed assets (TEUR 357,228, previous year TEUR 360,292) without affecting the annual result (for the subsidy-financed fixed assets). The difference corresponds to the depreciation and amortization of the fixed assets not covered by extraordinary items relating to NÖV and MPI for Psychiatry.

Extraordinary write-downs on tangible fixed assets were recognized in the amount of TEUR 395 (previous year TEUR 26).

## Other expenses

**Interest and similar expenses** (TEUR 16,193, previous year TEUR 17,195) consist almost entirely of interest expenses arising from the reversal of discounts to provisions (TEUR 16,190, previous year TEUR 17,192).

**Other operating expenses** of TEUR 585,406 (previous year TEUR 624,320) are comprised as follows:

	2019 TEUR	2018 TEUR
<b>Other operating expenses</b>		
Management of land and buildings	169,535	168,824
Libraries	16,786	20,435
Other research expenses	117,726	114,763
<i>of which</i>		
Travel costs	38,280	38,636
Conferences, advanced training	20,467	19,154
Publications, public relations	8,930	8,814
Other expenses for science and research purposes	50,049	48,159
Business requirements	79,236	75,391
Auditing and advisory costs	26,557	22,531
Further other expenses	30,944	42,502
Expenses from allocation to multi-year available funds	144,622	179,874

The **expenses for allocation to multi-year available funds** are attributable to the MPG excluding IPP and represent the balance of subsidy-financed income and expenses in the statement of profit and loss. They are comprised as follows: They are comprised as follows:

	TEUR
<b>Expenses for allocation to multi-year available funds</b>	
Basic funding	87,686
Special funding	6,117
Project funding	49,624
Undisbursed funds for operations pursuant to § 26 of the Federal Budget Ordinance (BHO) including MPI for Psychiatry	1,195
<b>TOTAL</b>	<b>144,622</b>

Other operating expenses include refunds of advance payments on taxes on income in the amount of TEUR 171.

## Transfers and subsidies granted

The MPG is authorized to transfer funding provided to it to various final recipients as a non-repayable subsidy.

Funding was transferred as follows in the reporting year:

	2019 TEUR	2018 TEUR
<b>TRANSFERS AND SUBSIDIES GRANTED</b>		
For institutional funding, MPG excluding IPP		
to institutions within Germany	13,766	9,255
to institutions abroad	19,452	22,002
For project funding, MPG excluding IPP		
in Germany	2,306	2,246
abroad	4,756	4,763
For the transfer of personnel due to closures/partial closures, MPG excluding IPP	0	153
Transferred IPP subsidies	0	3,166
<b>TOTAL</b>	<b>40,280</b>	<b>41,585</b>
<i>for information purposes: subsidies granted to internal institutions</i>	<i>26,042</i>	<i>29,772</i>

The subsidies granted to internal institutions were consolidated in the annual financial statements.

## Expenses from addition to the extraordinary item (subsidized investments)

**Expenses from addition to the extraordinary item to finance intangible and tangible fixed assets** (TEUR 340,617, previous year TEUR 321,984) represent the subsidized investments in these assets. They correlate in their entirety with the additions in the reporting year in accordance with the statement of changes in fixed assets (TEUR 340,358). The difference consists, firstly, of the additions to the NÖV (TEUR 106). Secondly, expenses from the addition to the extraordinary item to finance intangible and tangible fixed assets include subsequent capitalizations of the current year at their book value (TEUR 365), which are presented openly in separate columns in the statement of changes in fixed assets.

**Expenses from addition to the extraordinary item to finance financial assets and shares in spin-offs** (TEUR 214, previous year TEUR 1,451) result from expenses for the acquisition of shares in spin-offs.

---

## 5. Other disclosures

---

### Contingent liabilities and other financial obligations

No risks existed from off-balance sheet transactions as defined by § 285 No. 3 HGB or contingent liabilities pursuant to § 251 HGB as of the balance sheet date.

Regarding the Max Planck Digital Library, obligations arise of around EUR 173.6 million in the period covered by the medium-term budgetary accounting (2020 to 2024) for the MPG-wide basic supply of software and online services as well as literature. The licence contracts required for this purpose are of different durations.

Other financial obligations of around EUR 213.5 million also result from the perspective of the medium-term budgetary accounting of the MPG from the pro rata funding of jointly maintained institutions or joint ventures during scientific collaborations. In particular, this relates to: Deutsches Klimarechenzentrum GmbH, Gesellschaft für wissenschaftliche Datenverarbeitung mbH Göttingen, Institut de Radio Astronomie Millimétrique, Large Binocular Telescope and the Max Planck Florida Institute for Neuroscience.

The MPG appoints its top scientists for life and undertakes as part of the appointment to provide its scientists with funds for their basic scientific equipment. The announced call for these funds will result in possible obligations of around EUR 124.0 million within the timeframe of the medium-term budgetary accounting.

As of 31 December 2019, total construction costs budgeted but not yet disbursed amount to around EUR 658.8 million for major construction projects already commenced by Institutes and facilities.

Order obligations aside from construction projects total around EUR 58.2 million as of 31 December 2019.



## Employees

The MPG employed an average of 19,901 staff during the financial year:

	Number 2019	Number Previous year
Scientists	6,663	6,675
Doctoral students with funding contracts	3,157	2,930
Non-scientific staff	8,410	8,275
Student and graduate assistants	1,671	1,634
<b>EMPLOYEES</b> (excluding trainees and interns)	<b>19,901</b>	<b>19,514</b>
<i>for information purposes: Scholarship holders</i>	<i>641</i>	<i>883</i>

## Participations

The MPG holds shares in other companies or major international projects in order to exploit synergy effects for scientific assignments to the best possible long-term advantage.

As of 31 December 2019, the following shareholdings existed:

Name	Registered seat	Purpose	Share in the capital	Book value as of 31.12.2019 EUR
<b>SHARES IN AFFILIATED COMPANIES</b>				
Max-Planck-Innovation GmbH	Munich	The company manages and exploits intangible invention assets owned by the Max Planck Society.	100%	500,000
Minerva Stiftung Gesellschaft für die Forschung mbH	Munich	The purpose of the (non-profit) company is to fund science and research, on the one hand by providing financial support for research projects at home and abroad, and on the other by operating funding programmes, principally in Israel.	100%	26,000
Max-Planck-Stiftung für Internationalen Frieden und Rechtsstaatlichkeit gemeinnützige GmbH	Heidelberg	The purpose of the company is the advancement of science and research, the international ethos of tolerance and the concept of international understanding, development cooperation, public and professional education as well as democracy as a political system.	100%	25,000
Deutsches Klimarechenzentrum GmbH	Hamburg	The object and purpose of the (non-profit) company is the promotion of basic research and applied research in climatology and the disciplines immediately related to climatology. The purpose is achieved in particular through the expansion and operation of a climate computing centre.	54.5%	31,200
Max-Planck-Institut für Eisenforschung Gesellschaft mit beschränkter Haftung	Düsseldorf	This (non-profit) company conducts basic research in the field of iron, steel and related materials.	50%	13,000

Name	Registered seat	Purpose	Share in the capital	Book value as of 31.12.2019 EUR
<b>PARTICIPATIONS</b>				
Gesellschaft für wissenschaftliche Datenverarbeitung mbH Göttingen	Göttingen	This (non-profit) company promotes science and research. It fulfils the function of a computing and competence centre for the MPG and a university computing centre for the University of Göttingen.	50%	26,000
Max Planck Graduate Center mit der Johannes Gutenberg-Universität Mainz GmbH	Mainz	The object of the (non-profit) company is the advancement of science and research, in particular by means of interdisciplinary teaching and doctoral programmes for junior scientists.	50%	12,500
UltraFast Innovations GmbH	Garching	The object of the company is to develop and produce special mirror optics and filters with tailor-made properties for laser applications, as well as laser systems and measurement equipment in which these optics are used.	50%	12,500
Institut de Radio Astronomie Millimétrique	Grenoble/France	The object is the joint operation of two observation stations on Loma de Dilar (30-metre telescope) in Spain and on the Plateau de Bure (interferometer with seven 15-metre telescopes) in France as well as a science laboratory in Grenoble, France.	47%	716.75
EuResist Network GEIE	Rome/Italy	European Economic Interest Grouping, founded as part of the 7th EU research framework programme for the „CHAIN – Collaborative HIV and Anti-HIV Drug Resistance Network“ project.	20%	3,100.22
Wissenschaft im Dialog gGmbH	Berlin	The object of the company is to promote dialogue between science and society with special regard to the latest public forms of communication, to promote understanding between science, research and the public, information on the methods and processes of scientific research as well as to emphasize the mutual interactions and dependencies of science, business and society.	8.33%	5,000
Schloss Dagstuhl – Leibniz Zentrum für Informatik Gesellschaft mit beschränkter Haftung	Wadern	As an international meeting point and research centre for computer science, the task of this (non-profit) company is to conduct scientific computer science conferences.	7.70%	5,200
Cherenkov Telescope Array Observatory gemeinnützige GmbH	Heidelberg	The company is responsible for: <ul style="list-style-type: none"> <li>– developing the planning and preparing the realization of the CTAO Facility as well as the development of the founding accord for the construction and Operation of the CTAO Facility</li> <li>– selecting and equipping the telescope locations</li> <li>– planning and development as well as construction and operation of prototype telescopes and related instruments and infrastructure for test purposes</li> <li>– preparation of programmes for scientific research conducted in the CTAO Facility.</li> </ul>	5%	1,250
FIZ Karlsruhe – Leibniz Institut für Informationsinfrastruktur GmbH	Eggenstein-Leopoldshafen	The task of this (non-profit) company is to provide science and research with scientific information, develop corresponding products and services in the field of scientific information infrastructure and to make them publicly accessible.	3.26%	1,560
LSI Pre-Seed-Fonds GmbH	Bonn	LSI PSF GmbH operates together with Life Science Inkubator GmbH & Co. KG (management company Life Science Inkubator GmbH is a wholly-owned subsidiary of Max-Planck Innovation GmbH) an incubator for researchers from German universities and research facilities interested in founding their own company.	1.5%	220,000

Name	Registered seat	Purpose	Share in the capital	Book value as of 31.12.2019 EUR
Futurium gGmbH (formerly: Haus der Zukunft gGmbH)	Berlin	The company's purpose is to operate the Futurium as a location for presentations and dialog for science, research and development. Exhibitions and events are to make future-oriented scientific and technical developments of national and international significance visible, and present them for discussion.	1%	250

No details are given of these companies' equity or their results in the last financial year due to their subordinate significance in accordance with § 286 para. 3 sentence 1 No. 1 HGB.

The MPG refrains from preparing consolidated financial statements in the meaning of No. 14 (1) of the Management Principles for the MPG (BewGr-MPG), as the participations reported under the balance sheet item "shares in affiliated companies" are of subordinate significance, both individually as well as together, for the net assets, financial position and results of operations of the MPG.

---

## MPG Bodies in their tasks

The MPG Statutes specify the following bodies:

- the President,
- the Executive Committee,
- the Senate,
- the General Meeting,
- the Scientific Council and its Sections

The **President** represents the Max Planck Society, drafts the outlines of its science policy, and works to ensure trustful collaboration within the Max Planck Society. The President chairs the Senate, Executive Committee and General Meeting. In cases that cannot be deferred, the President may make decisions falling within these bodies' competency.

The **Executive Committee** advises the President and prepares resolutions for the Senate and the General Meeting. It prepares the overall budget and submits it to the Senate for adoption. It also prepares the annual report as well as the annual accounts for adoption by the Senate. Furthermore, through the President, it exercises a supervisory role over the Administrative Headquarters and possesses the decision-making power in all of the Society's matters that are not allocated to another body and that extend above and beyond current transactions to be managed by the Administrative Headquarters. Together with the Secretary General, it forms the Management Board in the meaning of the law.

The **Senate** is an important decision-making body of the Max Planck Society. The Senate elects the President and other members of the Executive Committee and decides on the appointment of the Secretary General. It decides on the foundation and closure of Institutes and Departments, the appointment of Scientific Members and the by-laws of the Institutes. The Senate decides on the involvement of the Max Planck Society in other institutions and approves the overall budget; it also approves the annual report and presents it to the General Meeting. It adopts the annual accounts and decides on the admission of Supporting Members. The Senate can also pass resolutions on all matters of the Max Planck Society that the Statutes do not reserve for the General Meeting. The voting-entitled members of the Senate include both Elected Senators and Ex officio Members. The Senate's composition reflects the aim to draw on experience from all important areas of public life in important decisions. For this reason, the Elected Senators – of whom there are a minimum of twelve and a maximum of 32 – include not only outstanding MPG scientists but also high-ranking representatives of the federal government and the federal states, important personalities from business enterprises and scientific organizations as well as other socially relevant groups.

The Senate is supported by three Senate Committees:

- The **Senate Committee for Research Planning** advises on questions of research policy and research planning.
- The **Audit Committee** reviews the lawfulness of budget implementation and the correctness of the Society's accounting, as well as the effectiveness of its risk and compliance management. It makes proposals to the General Meeting regarding the appointment of external auditors, determines the criteria and scope of the audit engagement and receives the external auditors' reports. It receives the annual report of the Internal Auditing Department and is authorized to prompt further audits.
- The task of the **Employment Committee** is to decide upon the reward of and upon the approval of ancillary activities undertaken by the President and upon the reward of and upon the approval of function-related ancillary activities undertaken by the other members of the Executive Committee. The Employment Committee is further tasked with deciding upon the reward of former Presidents in return for the performance of tasks for the Society.

The **General Meeting** (the meeting of its members) is the uppermost association body of the Max Planck Society. It decides on amendments to the Society's Statutes, elects the Senate members, receives the annual report, audits and approves the annual accounts, and grants approbation. The Society's members include its Scientific Members, Supporting Members, Ex officio Members, and Honorary Members.

The **Scientific Council** consists of Scientific Members and the heads of the Institutes and of research facilities equivalent to Institutes. It also comprises scientific staff elected by the Institutes to the Sections. The Emeritus Scientific Members and the External Scientific Members of the Institute may attend meetings as guests in an advisory capacity. The Scientific Council is divided into three Sections. The Sections' task is to discuss the Institutes' joint matters and prepare the Senate's scientific decisions through specialist recommendations.

Staff of the MPG governing bodies<sup>1</sup>**PRESIDENT**

**Martin Stratmann**, Prof. Dr., München, Wissenschaftliches Mitglied des Max-Planck-Instituts für Eisenforschung GmbH, Düsseldorf

**EXECUTIVE COMMITTEE**

## PRESIDENT – CHAIRPERSON

**Martin Stratmann**, Prof. Dr., München, Wissenschaftliches Mitglied des Max-Planck-Instituts für Eisenforschung GmbH, Düsseldorf

## VICE PRESIDENTS

**Andreas Barner**, Prof. Dr. Dr., Mitglied des Gesellschafterausschusses der C. H. Boehringer Sohn AG & Co. KG, Ingelheim am Rhein, und Präsident des Stifterverbandes für die Deutsche Wissenschaft e. V., Essen

**Angela D. Friederici**, Prof. Dr., Wissenschaftliches Mitglied und Direktorin am Max-Planck-Institut für Kognitions- und Neurowissenschaften, Leipzig

**Bill S. Hansson**, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für chemische Ökologie, Jena

**Ferdi Schüth**, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Kohlenforschung (rechtsfähige Stiftung), Mülheim/Ruhr

## TREASURER

**Ralf P. Thomas**, Prof. Dr., Mitglied des Vorstands und Chief Financial Officer der Siemens AG, München

## OTHER MEMBERS

**Nikolaus von Bomhard**, Dr., Vorsitzender des Aufsichtsrats der Münchner Rückversicherungs-Gesellschaft, München

**Stefan von Holtzbrinck**, Dr., Vorsitzender der Geschäftsführung der Verlagsgruppe Georg von Holtzbrinck GmbH, Stuttgart

**MANAGEMENT BOARD**

Together with Secretary General **Rüdiger Willems**, München, the Executive Committee formed the Management Board in the spirit of the law.

**SENATE**

## CHAIRPERSON

**Martin Stratmann**, Prof. Dr., Präsident der Max-Planck-Gesellschaft, München, Wissenschaftliches Mitglied des Max-Planck-Instituts für Eisenforschung GmbH, Düsseldorf

## ELECTED SENATORS

**Frank Appel**, Dr., Vorstandsvorsitzender der Deutschen Post DHL Group, Bonn

**Andreas Barner**<sup>2</sup>, Prof. Dr. Dr., Vizepräsident der Max-Planck-Gesellschaft, Mitglied des Gesellschafterausschusses der C. H. Boehringer Sohn AG & Co. KG, Ingelheim am Rhein, und Präsident des Stifterverbandes für die Deutsche Wissenschaft e. V., Essen

**Theresia Bauer**<sup>3</sup>, MdL, Ministerin für Wissenschaft, Forschung und Kunst des Landes Baden-Württemberg, Stuttgart

**Ulrike Beisiegel**, Prof. Dr. Dr. h. c., ehem. Präsidentin der Universität Göttingen, Hamburg

**Nikolaus von Bomhard**, Dr., Mitglied des Verwaltungsrats der Max-Planck-Gesellschaft, Vorsitzender des Aufsichtsrats der Münchener Rückversicherungs-Gesellschaft, München

**Martin Bruder Müller**, Dr., Vorstandsvorsitzender der BASF SE, Ludwigshafen

**Thomas Enders**, Dr., ehem. Chief Executive Officer der Airbus Group, Blagnac, Frankreich

**Angela D. Friederici**, Prof. Dr., Vizepräsidentin der Max-Planck-Gesellschaft, Wissenschaftliches Mitglied und Direktorin am Max-Planck-Institut für Kognitions- und Neurowissenschaften, Leipzig

**Joachim Gauck**, Bundespräsident a. D. der Bundesrepublik Deutschland, Berlin

<sup>1</sup>The dates in brackets show the date of leaving (until/bis) or joining (since/seit) the respective governing body.

<sup>2</sup>Prof. Barner ist zugleich ständiger Gast des Senats der Max-Planck-Gesellschaft als Präsident des Stifterverbandes für die Deutsche Wissenschaft e. V.

<sup>3</sup>Frau Bauer ist zugleich ständiger Gast des Senats der Max-Planck-Gesellschaft als Vertreterin der Länder.

**Sibylle Günter**, Prof. Dr., Wissenschaftliches Mitglied und Wissenschaftliche Direktorin des Max-Planck-Instituts für Plasma-physik, Garching

**Bill S. Hansson**, Prof. Dr., Vizepräsident der Max-Planck-Gesellschaft, Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für chemische Ökologie, Jena

**Franz-Ulrich Hartl**, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Biochemie, Martinsried

**Wolfgang A. Herrmann**, Prof. Dr. Dr. h.c. mult., ehem. Präsident der Technischen Universität München, München

**Stefan von Holtzbrinck**, Dr., Mitglied des Verwaltungsrats der Max-Planck-Gesellschaft, Vorsitzender der Geschäftsführung der Verlagsgruppe Georg von Holtzbrinck GmbH, Stuttgart

**Berthold Huber**, ehem. Erster Vorsitzender der IG Metall, Frankfurt/Main

**Henning Kagermann**, Prof. Dr. Dr.-Ing. e.h., Vorsitzender des Kuratoriums der acatech – Deutsche Akademie der Technikwissenschaften, München

**Regine Kahmann**, Prof. Dr., Emeritiertes Wissenschaftliches Mitglied des Max-Planck-Instituts für terrestrische Mikrobiologie, Marburg

**Jürgen Kaube**, Mitherausgeber der Frankfurter Allgemeinen Zeitung, Frankfurt/Main

**Annegret Kramp-Karrenbauer**, Bundesministerin der Verteidigung, Vorsitzende der CDU Deutschland, Berlin

**Nicola Leibinger-Kammüller**, Dr., Vorsitzende der Geschäftsführung der TRUMPF GmbH & Co. KG, Ditzingen

**Anton Losinger**, Dr. Dr., Weihbischof des Bistums Augsburg, Augsburg

**Angelika Niebler**, Prof. Dr., MdEP, Mitglied des Europäischen Parlaments, Vaterstetten

**Norbert Reithofer**, Dr.-Ing. Dr.-Ing. E.h., Vorsitzender des Aufsichtsrats der Bayerischen Motoren Werke Aktiengesellschaft, München

**Ferdi Schüth**, Prof. Dr., Vizepräsident der Max-Planck-Gesellschaft, Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Kohlenforschung (rechtsfähige Stiftung), Mülheim/Ruhr

**Peter Seeberger**, Prof. Dr., Wissenschaftliches Mitglied und Geschäftsführender Direktor des Max-Planck-Instituts für Kolloid- und Grenzflächenforschung, Potsdam

**Ralf P. Thomas**, Prof. Dr., Schatzmeister der Max-Planck-Gesellschaft, Mitglied des Vorstands und Chief Financial Officer der Siemens AG, München

**Stanislaw Tillich**, Ministerpräsident a.D. des Freistaates Sachsen, Dresden

**Andreas Voßkuhle**, Prof. Dr., Präsident des Bundesverfassungsgerichts, Karlsruhe

**Daniel Zajfman**, Prof. Dr., Auswärtiges Wissenschaftliches Mitglied des Max-Planck-Instituts für Kernphysik, Heidelberg, Chair of the Academic Board of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot, Israel

**Reinhard Zimmermann**, Prof. Dr. Dr. h.c. mult., Wissenschaftliches Mitglied und Geschäftsführender Direktor des Max-Planck-Instituts für ausländisches und internationales Privatrecht, Hamburg

**Maciej Zyllicz**, Prof. Dr. Dr. h.c., President and Executive Director of the Foundation for Polish Science, Warschau, Polen

#### EX OFFICIO MEMBERS

**Hubert Aiwanger**, Bayerischer Staatsminister für Wirtschaft, Landesentwicklung und Energie, München, als Vertreter der Länder

**Ulrich Becker**, Prof. Dr. LL.M. (EHI), Wissenschaftliches Mitglied und Geschäftsführender Direktor des Max-Planck-Instituts für Sozialrecht und Sozialpolitik, München, als Vorsitzender der Geistes-, Sozial- und Humanwissenschaftlichen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft (seit 28.06.2019)

**Gabriele Bixel**, Priv.-Doz. Dr., wissenschaftliche Mitarbeiterin am Max-Planck-Institut für molekulare Biomedizin, Münster, als Vertreterin der wissenschaftlichen Mitarbeiterinnen und Mitarbeiter der Biologisch-Medizinischen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft (seit 28.06.2019)

**Tobias Bonhoeffer**, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Neurobiologie, Martinsried, als Vorsitzender des Wissenschaftlichen Rates der Max-Planck-Gesellschaft

**Markus Burtscheidt**, als Vorsitzender des Gesamtbetriebsrates der Max-Planck-Gesellschaft, Köln

**Peter Fratzl**, Prof. Dr. Dr. h. c., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Kolloid- und Grenzflächenforschung, Potsdam, als Vorsitzender der Chemisch-Physikalisch-Technischen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft

**Werner Gatzert**, Staatssekretär im Bundesministerium der Finanzen, Berlin, als Vertreter des Bundes

**Hana Gründler**, Dr., Permanent Senior Research Scholar am Kunsthistorischen Institut in Florenz – Max-Planck-Institut, Florenz, Italien, als Vertreterin der wissenschaftlichen Mitarbeiterinnen und Mitarbeiter der Geistes-, Sozial- und Humanwissenschaftlichen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft (seit 28.06.2019)

**Anja Karliczek**, MdB, Bundesministerin für Bildung und Forschung, Berlin, als Vertreterin des Bundes

**Matthias Kollatz**, Dr., MdA, Senator für Finanzen des Landes Berlin, Berlin, als Vertreter der Länder

**Ariane Leendertz**, Dr., Leiterin einer Minerva-Forschungsgruppe am Max-Planck-Institut für Gesellschaftsforschung, Köln, als Vertreterin der wissenschaftlichen Mitarbeiterinnen und Mitarbeiter der Geistes-, Sozial- und Humanwissenschaftlichen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft (bis 07.01.2019)

**Martina Münch**, Dr., Ministerin für Wissenschaft, Forschung und Kultur des Landes Brandenburg, Potsdam, als Vertreterin der Länder (bis 20.11.2019)

**Jürgen Renn**, Prof. Dr., Wissenschaftliches Mitglied und Geschäftsführender Direktor des Max-Planck-Instituts für Wissenschaftsgeschichte, Berlin, als Vorsitzender der Geistes-, Sozial- und Humanwissenschaftlichen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft (bis 27.06.2019)

**Eduardo Ros Ibarra**, Prof. Dr., wissenschaftlicher Mitarbeiter am Max-Planck-Institut für Radioastronomie, Bonn, als Vertreter der wissenschaftlichen Mitarbeiterinnen und Mitarbeiter der Chemisch-Physikalisch-Technischen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft (ab 28.06.2019)

**Udo von Toussaint**, Priv.-Doz. Dr., Leiter einer Arbeitsgruppe am Max-Planck-Institut für Plasmaphysik, Garching, als Vertreter der wissenschaftlichen Mitarbeiterinnen und Mitarbeiter der Chemisch-Physikalisch-Technischen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft (bis 27.06.2019)

**Rüdiger Willems**, als Generalsekretär der Max-Planck-Gesellschaft, München

**Lothar Willmitzer**, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für molekulare Pflanzenphysiologie, Potsdam, als Vorsitzender der Biologisch-Medizinischen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft

**Carsten T. Wotjak**, Dr., Forschungsgruppenleiter am Max-Planck-Institut für Psychiatrie, München, als Vertreter der wissenschaftlichen Mitarbeiterinnen und Mitarbeiter der Biologisch-Medizinischen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft (bis 27.06.2019)

#### SENATORS WITHOUT VOTING RIGHTS

#### HONORARY MEMBERS

**Peter Gruss**, Prof. Dr., Martinsried, Präsident der Max-Planck-Gesellschaft von 2002 bis 2014, Emeritiertes Wissenschaftliches Mitglied des Max-Planck-Instituts für biophysikalische Chemie (Karl-Friedrich-Bonhoeffer-Institut), Präsident des Okinawa Institute of Science and Technology Graduate University

**Reimar Lüst**, Prof. Dr. Dr. h. c. mult., Hamburg, Präsident der Max-Planck-Gesellschaft von 1972 bis 1984, Emeritiertes Wissenschaftliches Mitglied des Max-Planck-Instituts für extraterrestrische Physik (verstorben)

**Reinhard Pöllath**, Prof. Dr., Rechtsanwalt, Kanzlei P+P Pöllath + Partners, München

#### HONORARY SENATOR

**Ernst-Joachim Mestmäcker**, Prof. Dr. Dr. h. c., Emeritiertes Wissenschaftliches Mitglied des Max-Planck-Instituts für ausländisches und internationales Privatrecht, Hamburg

#### PERMANENT GUESTS OF THE SENATE

**Peter-André Alt**, Prof. Dr., als Präsident der Hochschulrektorenkonferenz, Bonn

**Andreas Barner**<sup>4</sup>, Prof. Dr. Dr., Vizepräsident der Max-Planck-Gesellschaft, Mitglied des Gesellschafterausschusses der C. H. Boehringer Sohn AG & Co. KG, Ingelheim am Rhein, als Präsident des Stifterverbandes für die Deutsche Wissenschaft e. V., Essen

**Theresia Bauer**<sup>5</sup>, MdL, Ministerin für Wissenschaft, Forschung und Kunst des Landes Baden-Württemberg, Stuttgart, als Vertreterin der Länder

**Martina Brockmeier**, Prof. Dr., als Vorsitzende des Wissenschaftsrates, Köln

**Jörg Hacker**, Prof. Dr. Dr. h. c. mult., Auswärtiges Wissenschaftliches Mitglied des Max-Planck-Instituts für Infektionsbiologie, Berlin, Deutsche Akademie der Naturforscher Leopoldina, Halle (Saale), als Präsident der Nationalen Akademie der Wissenschaften

**Matthias Kleiner**, Prof. Dr.-Ing., als Präsident der Leibniz-Gemeinschaft, Berlin

**Wolf-Dieter Lukas**, Prof. Dr., Staatssekretär im Bundesministerium für Bildung und Forschung, Bonn, als Vertreter des Bundes (seit 01.11.2019)

**Reimund Neugebauer**, Prof. Dr.-Ing., als Präsident der Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V., München

**Georg Schütte**, Dr., Staatssekretär im Bundesministerium für Bildung und Forschung, Bonn, als Vertreter des Bundes (bis 31.10.2019)

**Peter Strohschneider**, Prof. Dr., als Präsident der Deutschen Forschungsgemeinschaft, Bonn

**Wolfgang Tiefensee**, Thüringer Minister für Wirtschaft, Wissenschaft und Digitale Gesellschaft, Erfurt, als Vertreter der Länder

**Otmar D. Wiestler**, Prof. Dr. Dr. h. c., als Präsident der Hermann von Helmholtz-Gemeinschaft Deutscher Forschungszentren e. V., Berlin

## SENATE COMMITTEES

### SENATE COMMITTEE FOR RESEARCH PLANNING

#### CHAIRPERSON

**Martin Stratmann**, Prof. Dr., Präsident der Max-Planck-Gesellschaft, München, Wissenschaftliches Mitglied des Max-Planck-Instituts für Eisenforschung GmbH, Düsseldorf

#### EX OFFICIO MEMBERS

**Andreas Barner**, Prof. Dr. Dr., Vizepräsident der Max-Planck-Gesellschaft, Mitglied des Gesellschafterausschusses der C. H. Boehringer Sohn AG & Co. KG, Ingelheim am Rhein, und Präsident des Stifterverbandes für die Deutsche Wissenschaft e. V., Essen

**Gabriele Bixel**, Priv.-Doz. Dr., wissenschaftliche Mitarbeiterin am Max-Planck-Institut für molekulare Biomedizin, Münster, als Vertreterin der wissenschaftlichen Mitarbeiterinnen und Mitarbeiter der Biologisch-Medizinischen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft (seit 28.06.2019)

**Tobias Bonhoeffer**, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Neurobiologie, Martinsried, als Vorsitzender des Wissenschaftlichen Rates der Max-Planck-Gesellschaft

**Peter Fratzl**, Prof. Dr. Dr. h. c., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Kolloid- und Grenzflächenforschung, Potsdam, als Vorsitzender der Chemisch-Physikalisch-Technischen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft

**Angela D. Friederici**, Prof. Dr., Vizepräsidentin der Max-Planck-Gesellschaft, Wissenschaftliches Mitglied und Direktorin am Max-Planck-Institut für Kognitions- und Neurowissenschaften, Leipzig

**Hana Gründler**, Dr., Permanent Senior Research Scholar am Kunsthistorischen Institut in Florenz – Max-Planck-Institut, Florenz, Italien, als Vertreterin der wissenschaftlichen Mitarbeiterinnen und Mitarbeiter der Geistes-, Sozial- und Humanwissenschaftlichen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft (seit 28.06.2019)

**Bill S. Hansson**, Prof. Dr., Vizepräsident der Max-Planck-Gesellschaft, Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für chemische Ökologie, Jena

<sup>4</sup> Prof. Barner ist zugleich Wahlsenator der Max-Planck-Gesellschaft.

<sup>5</sup> Frau Bauer ist zugleich Wahlsenatorin der Max-Planck-Gesellschaft.



**Ariane Leendertz**, Dr., Leiterin einer Minerva-Forschungsgruppe am Max-Planck-Institut für Gesellschaftsforschung, Köln, als Vertreterin der wissenschaftlichen Mitarbeiterinnen und Mitarbeiter der Geistes-, Sozial- und Humanwissenschaftlichen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft (bis 07.01.2019)

**Ulrich Becker**, Prof. Dr. LL. M. (EHI), Wissenschaftliches Mitglied und Geschäftsführender Direktor des Max-Planck-Instituts für Sozialrecht und Sozialpolitik, München, als Vorsitzender der Geistes-, Sozial- und Humanwissenschaftlichen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft (seit 28.06.2019)

**Jürgen Renn**, Prof. Dr., Wissenschaftliches Mitglied und Geschäftsführender Direktor des Max-Planck-Instituts für Wissenschaftsgeschichte, Berlin, als Vorsitzender der Geistes-, Sozial- und Humanwissenschaftlichen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft (bis 27.06.2019)

**Eduardo Ros Ibarra**, Prof. Dr., wissenschaftlicher Mitarbeiter am Max-Planck-Institut für Radioastronomie, Bonn, als Vertreter der wissenschaftlichen Mitarbeiterinnen und Mitarbeiter der Chemisch-Physikalisch-Technischen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft (seit 28.06.2019)

**Ferdi Schüth**, Prof. Dr., Vizepräsident der Max-Planck-Gesellschaft, Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Kohlenforschung (rechtsfähige Stiftung), Mülheim an der Ruhr

**Udo von Toussaint**, Priv.-Doz. Dr., Leiter einer Arbeitsgruppe am Max-Planck-Institut für Plasmaphysik, Garching, als Vertreter der wissenschaftlichen Mitarbeiterinnen und Mitarbeiter der Chemisch-Physikalisch-Technischen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft (bis 27.06.2019)

**Rüdiger Willems**, Generalsekretär der Max-Planck-Gesellschaft, München

**Lothar Willmitzer**, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für molekulare Pflanzenphysiologie, Potsdam, als Vorsitzender der Biologisch-Medizinischen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft

**Carsten T. Wotjak**, Dr., Forschungsgruppenleiter am Max-Planck-Institut für Psychiatrie, München, als Vertreter der wissenschaftlichen Mitarbeiterinnen und Mitarbeiter der Biologisch-Medizinischen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft (bis 27.06.2019)

#### MEMBERS ELECTED BY THE SENATE

**Ulrike Beisiegel**, Prof. Dr. Dr. h. c., ehem. Präsidentin der Universität Göttingen, Hamburg

**Henning Kagermann**, Prof. Dr. Dr.-Ing. e. h., Vorsitzender des Kuratoriums der acatech – Deutsche Akademie der Technikwissenschaften, Berlin, als Wahlsenator der Max-Planck-Gesellschaft

**Anton Losinger**, Dr. Dr., Weihbischof des Bistums Augsburg, Augsburg

**Andreas Voßkuhle**, Prof. Dr., Präsident des Bundesverfassungsgerichts, Karlsruhe

**Daniel Zajfman**, Prof. Dr., Auswärtiges Wissenschaftliches Mitglied des Max-Planck-Instituts für Kernphysik, Heidelberg, Chair of the Academic Board of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot, Israel

**Maciej Zylicz**, Prof. Dr. Dr. h. c., President and Executive Director of the Foundation for Polish Science, Warschau, Polen

#### AUDIT COMMITTEE OF THE SENATE

**Clemens Börsig**, Prof. Dr. rer. pol., ehem. Aufsichtsratsvorsitzender der Deutschen Bank, Frankfurt/Main, als Förderndes Mitglied der Max-Planck-Gesellschaft

**Henning Kagermann**, Prof. Dr. Dr.-Ing. e. h., Vorsitzender des Kuratoriums der acatech – Deutsche Akademie der Technikwissenschaften, Berlin, als Wahlsenator der Max-Planck-Gesellschaft

**Anton Losinger**, Dr. Dr., Weihbischof des Bistums Augsburg, Augsburg, als Wahlsenator der Max-Planck-Gesellschaft

#### EMPLOYMENT COMMITTEE OF THE SENATE

**Martin Bruder Müller**, Dr., Vorstandsvorsitzender der BASF SE, Ludwigshafen, als Wahlsenator der Max-Planck-Gesellschaft

**Berthold Huber**, ehem. Erster Vorsitzender der IG Metall, Frankfurt/Main, als Wahlsenator der Max-Planck-Gesellschaft

**Reinhard Pöllath**, Prof. Dr., Ehrenmitglied des Senats der Max-Planck-Gesellschaft, Rechtsanwalt, Kanzlei P+P Pöllath + Partners, München, als Förderndes Mitglied der Max-Planck-Gesellschaft

## GENERAL MEETING

### CHAIRPERSON

**Martin Stratmann**, Prof. Dr., Präsident der Max-Planck-Gesellschaft, München, Wissenschaftliches Mitglied des Max-Planck-Instituts für Eisenforschung GmbH, Düsseldorf

### MEMBERS

The General Meeting consists of the Members of the Max-Planck-Gesellschaft. These are: Supporting Members, Scientific Members, Ex officio Members and Honorary Members.

## SCIENTIFIC COUNCIL

### CHAIRPERSON

**Tobias Bonhoeffer**, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Neurobiologie, Martinsried

### VICE CHAIRPERSON

**Bernhard Keimer**, Honorarprof. Ph.D., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Festkörperforschung, Stuttgart

## BIOLOGY & MEDICINE SECTION

### CHAIRPERSON

**Lothar Willmitzer**, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für molekulare Pflanzenphysiologie, Potsdam

### VICE CHAIRPERSON

**Andrea Musacchio**, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für molekulare Physiologie, Dortmund

### MEDIATORS

**Ralf Conrad**, Prof. Dr., Emeritiertes Wissenschaftliches Mitglied des Max-Planck-Instituts für terrestrische Mikrobiologie, Marburg

**Franz-Ulrich Hartl**, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Biochemie, Martinsried

**Gerhard Mittler**, Dr., wissenschaftlicher Mitarbeiter des Max-Planck-Instituts für Immunbiologie und Epigenetik, Freiburg (bis 27.06.2019)

**Camila Caldana**, Dr., wissenschaftliche Mitarbeiterin des Max-Planck-Instituts für molekulare Pflanzenphysiologie, Potsdam (seit 28.06.2019)

## CHEMISTRY, PHYSICS & TECHNOLOGY SECTION

### CHAIRPERSON

**Peter Fratzl**, Prof. Dr. Dr. h. c., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Kolloid- und Grenzflächenforschung, Potsdam

### VICE CHAIRPERSON

**Peter Druschel**, Prof. Ph. D., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Softwaresysteme, Saarbrücken

### MEDIATORS

**Gerhard Dehm**, Univ.-Prof. Dipl.-Ing. Dr., Wissenschaftliches Mitglied am Max-Planck-Institut für Eisenforschung GmbH, Düsseldorf (seit 22.11.2019)

**Gerd Leuchs**, Prof. Dr., als Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für die Physik des Lichts, Erlangen (bis 01.04.2019) und als Emeritiertes Wissenschaftliches Mitglied ab 22.11.2019

**Stefan Luther**, Prof. Dr., wissenschaftlicher Mitarbeiter des Max-Planck-Instituts für Dynamik und Selbstorganisation, Göttingen (bis 27.06.2019)

**Walther Thiel**, Prof. Dr., Emeritiertes Wissenschaftliches Mitglied des Max-Planck-Instituts für Kohlenforschung (rechtsfähige Stiftung), Mülheim/Ruhr (bis 23.08.2019, verstorben)

**Johannes Wicht**, Dr., wissenschaftlicher Mitarbeiter des Max-Planck-Instituts für Physik des Lichts, Erlangen (seit 22.11.2019)

## HUMAN SCIENCES SECTION

### CHAIRPERSON

**Jürgen Renn**, Prof. Dr., Wissenschaftliches Mitglied und Geschäftsführender Direktor des Max-Planck-Instituts für Wissenschaftsgeschichte, Berlin (bis 27.06.2019)

**Ulrich Becker**, Prof. Dr. LL. M. (EHI), Wissenschaftliches Mitglied und Geschäftsführender Direktor des Max-Planck-Instituts für Sozialrecht und Sozialpolitik, München (seit 28.06.2019)

### VICE CHAIRPERSON

**Ulrich Becker**, Prof. Dr. LL. M. (EHI), Wissenschaftliches Mitglied und Geschäftsführender Direktor des Max-Planck-Instituts für Sozialrecht und Sozialpolitik, München (bis 27.06.2019)

**Jürgen Renn**, Prof. Dr., Wissenschaftliches Mitglied und Geschäftsführender Direktor des Max-Planck-Instituts für Wissenschaftsgeschichte, Berlin (seit 28.06.2019)

## MEDIATORS

**Fabian Gaessler**, Dr., wissenschaftlicher Mitarbeiter des  
Max-Planck-Instituts für Innovation und Wettbewerb, München

**Wolfgang Klein**, Prof. Dr., Emeritiertes Wissenschaftliches Mit-  
glied des Max-Planck-Instituts für Psycholinguistik, Nijmegen,  
Niederlande (seit 28.06.2019)

**Antje-Susanne Meyer**, Prof. Dr., Wissenschaftliches Mitglied  
und Direktorin am Max-Planck-Institut für Psycholinguistik,  
Nijmegen, Niederlande

**Wolfgang Prinz**, Prof. Dr., Steinhagen, Emeritiertes Wissen-  
schaftliches Mitglied des Max-Planck-Instituts für Kognitions-  
und Neurowissenschaften (bis 27.06.2019)

---

## Additional information

Total emoluments for the President, Vice President and Secretary General for their work on the Management Board and Executive Committee amounted to TEUR 590 for the calendar year 2019. Total emoluments for former members of the Management Board or Executive Committee (Civil Servant-type pensions and benefits for surviving dependants) amounted to TEUR 503. Provisions amounting to TEUR 3,773 exist for pension obligations to former members of the Management Board or Executive Committee. The Treasurer and other members of the Executive Committee did not receive any emoluments for their work on the Management Board and Executive Committee. Members of the Senate also received no emoluments for their work in the Senate.

The total fee for the auditor in the 2019 financial year amounted to TEUR 187. This related exclusively to work performed for the auditing of the annual financial statements.

No transactions of any material significance to the MPG were realized on non-standard terms with affiliated companies or persons.

The MPG holds all shares in the special securities assets fund DeAM-Fonds PMF 1 ISIN DE0008498080. The fund consists of two segments, "DBA" and "Others". Around 85% of the securities investments were actively managed in the DBA segment by a manager. The other securities investments in the Others segment are distributed across institutional funds in a diversified portfolio in accordance with the advisory support of an Investment Advisory Board. All securities assets are allocated in accordance with defined investment guidelines paying special attention to the criteria of risk, return and ongoing dividends. As of 31 December 2019, the market value stood at EUR 169.85 million. The difference between this and the book value (EUR 131.88 million) amounted to EUR 37.97 million. No write-downs were required. The income generated in the 2019 reporting year from the special fund amounted to EUR 4.27 million. No restrictions of any legal or actual kind exist with regard to the redemption of shares.

## Events of particular significance after the end of the financial year

The corona pandemic is presently having a severe impact on the operational research activities at the Institutes. Considerable delays have already been encountered in current scientific and non-scientific projects, up to the concrete risk of interruption.

**Berlin, 24 April 2020**

**Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin**  
**– The Executive Committee –**

Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin

Annex to the notes to the financial statements

# STATEMENT OF CHANGES IN FIXED ASSETS AS OF 31 DECEMBER 2019

	COSTS OF PURCHASING OR MANUFACTURING					
	Balance on 01.01.2019 EUR	Addition 2019 EUR	Subsequent capitalization 2019 EUR	Disposal 2019 EUR	Rebooking 2019 EUR	Balance on 31.12.2019 EUR
<b>I. INTANGIBLE ASSETS</b>						
1. Purchased concessions, industrial property rights and similar rights and assets, as well as licences to such rights and assets	71,365,353.95	7,571,042.31	31,972.98	-3,897,522.44	473,978.48	75,544,825.28
2. Prepayments made	1,014,758.06	1,143,690.11	0.00	0.00	-785,054.24	1,373,393.93
	<b>72,380,112.01</b>	<b>8,714,732.42</b>	<b>31,972.98</b>	<b>-3,897,522.44</b>	<b>-311,075.76</b>	<b>76,918,219.21</b>
<b>II. TANGIBLE FIXED ASSETS</b>						
1. Land, rights equivalent to land, and buildings including buildings on third-party land	2,550,844,997.11	8,374,217.17	6,500.79	-3,483,255.69	25,959,574.94	2,581,702,034.32
2. Technical plant and machinery	2,919,125,583.49	122,970,520.85	1,992,640.28	-61,487,378.53	31,695,292.46	3,014,296,658.55
3. Other plant, operating and office equipment	1,020,189,795.56	65,925,045.35	141,857.56	-31,258,149.08	2,544,106.83	1,057,542,656.22
4. Prepayments made and plant under construction	177,671,294.94	134,373,885.95	238,445.00	-665,635.55	-59,887,898.47	251,730,091.87
	<b>6,667,831,671.10</b>	<b>331,643,669.32</b>	<b>2,379,443.63</b>	<b>-96,894,418.85</b>	<b>311,075.76</b>	<b>6,905,271,440.96</b>
<b>III. FINANCIAL ASSETS</b>						
1. Shares in affiliated companies	595,200.00	0.00	0.00	0.00	0.00	595,200.00
2. Participations	288,076.97	0.00	0.00	0.00	0.00	288,076.97
3. Investment securities	129,785,160.12	2,614,999.03	0.00	-516,134.17	0.00	131,884,024.98
4. Other loans and shares	2,694,040.21	508,300.00	0.00	-1,336,048.80	0.00	1,866,291.41
	<b>133,362,477.30</b>	<b>3,123,299.03</b>	<b>0.00</b>	<b>-1,852,182.97</b>	<b>0.00</b>	<b>134,633,593.36</b>
<b>TOTAL</b>	<b>6,873,574,260.41</b>	<b>343,481,700.77</b>	<b>2,411,416.61</b>	<b>-102,644,124.26</b>	<b>0.00</b>	<b>7,116,823,253.53</b>

DEPRECIATION AND AMORTIZATION							BOOK VALUES		
Accumulated 01.01.2019 EUR	Financial year 2019 EUR	to subsequent capitalization 2019 EUR	to disposal 2019 EUR	to rebooking 2019 EUR	Write-up 2019 EUR	Accumulated 31.12.2019 EUR	Balance on 31.12.2019 EUR	Balance on 01.01.2019 EUR	
- 58,564,609.33	- 8,734,242.90	- 10,752.98	3,876,443.44	3,976.90	0.00	- 63,429,184.87	12,115,640.41	12,800,744.62	
0.00	0.00	0.00	0.00	0.00	0.00	0.00	1,373,393.93	1,014,758.06	
<b>- 58,564,609.33</b>	<b>- 8,734,242.90</b>	<b>- 10,752.98</b>	<b>3,876,443.44</b>	<b>3,976.90</b>	<b>0.00</b>	<b>- 63,429,184.87</b>	<b>13,489,034.34</b>	<b>13,815,502.68</b>	
- 1,283,100,370.05	- 69,846,064.58	- 6,500.79	1,117,412.28	- 2,583,771.12	0.00	- 1,354,419,294.26	1,227,282,740.06	1,267,744,627.06	
- 2,390,820,880.76	- 188,603,271.53	- 1,903,581.67	59,655,825.77	- 736,038.12	813,382.55	- 2,521,594,563.76	492,702,094.79	528,304,702.73	
- 803,285,172.74	- 91,312,440.15	- 125,290.32	30,859,681.77	3,315,832.34	3,631.40	- 860,543,757.70	196,998,898.52	216,904,622.82	
0.00	0.00	0.00	0.00	0.00	0.00	0.00	251,730,091.87	177,671,294.94	
<b>- 4,477,206,423.55</b>	<b>- 349,761,776.26</b>	<b>- 2,035,372.78</b>	<b>91,632,919.82</b>	<b>- 3,976.90</b>	<b>817,013.95</b>	<b>- 4,736,557,615.72</b>	<b>2,168,713,825.24</b>	<b>2,190,625,247.55</b>	
0.00	0.00	0.00	0.00	0.00	0.00	0.00	595,200.00	595,200.00	
0.00	0.00	0.00	0.00	0.00	0.00	0.00	288,076.97	288,076.97	
0.00	0.00	0.00	0.00	0.00	0.00	0.00	131,884,024.98	129,785,160.12	
0.00	0.00	0.00	0.00	0.00	0.00	0.00	1,866,291.41	2,694,040.21	
<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>134,633,593.36</b>	<b>133,362,477.30</b>	
<b>- 4,535,771,032.88</b>	<b>- 358,496,019.16</b>	<b>- 2,046,125.76</b>	<b>95,509,363.26</b>	<b>0.00</b>	<b>817,013.95</b>	<b>- 4,799,986,800.59</b>	<b>2,316,836,452.94</b>	<b>2,337,803,227.53</b>	

# INDEPENDENT AUDITOR'S REPORT

To the Max Planck Society for the Advancement of Science  
(Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.), Berlin

## Audit opinions

We have audited the annual financial statements, of the Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin, comprising the balance sheet as at 31 December 2019, the statement of profit and loss for the financial year from 1 January to 31 December 2019, and the notes to the annual financial statements, including the presentation of the accounting policies. In addition, we have audited the management report of the Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin, for the financial year from 1 January to 31 December 2019.

In our opinion, on the basis of the knowledge obtained in the audit,

- the enclosed annual financial statements comply in all significant respects with the German commercial law regulations applicable to corporations and gives a true and fair view pursuant to the German principles of proper accounting of the net assets and financial position of the association as of 31 December 2019 as well as of the results of operations for the financial year from 1 January to 31 December 2019, and
- the enclosed management report as a whole provides a suitable view of the association's position. In all significant respects, the management report is consistent with the annual financial statements, complies with German statutory regulations and suitably presents the opportunities and risks of future development.

Pursuant to § 322 para. 3 sentence 1 German Commercial Code (HGB), we declare that our audit has not led to reservations against the correctness of the annual financial statements and of the management report.

## Basis for the audit opinions

We conducted our audit of the annual financial statements and of the management report in accordance with § 317 HGB and in compliance with German generally accepted standards for the audit of financial statements promulgated by the Institute of Public Auditors in Germany (IDW). Our responsibility under these regulations and principles are further described in "The auditor's responsibility for the audit of the annual financial statements and the management report" section of our auditor's report. We are independent of the association in accordance with the German commercial law and professional law regulations and we have fulfilled our other German professional obligations in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinions on the annual financial statements and on the management report.

## Responsibility of the Executive Committee and of the Audit Committee for the annual financial statements and the management report

The Executive Committee is responsible for the preparation of the annual financial statements that comply, in all significant respects, with the German commercial law regulations applicable to corporations, and for the annual financial statements that give a true and fair view of the net assets, financial position and results of operations of the association in accordance with

German principles of proper accounting. Furthermore, the Executive Committee is responsible for such internal controls as they, in accordance with German principles of proper accounting, have determined necessary to permit the preparation of annual financial statements that are free from material misstatements, whether intentional or unintentional.

In preparing the annual financial statements, the Executive Committee is responsible for assessing the association's ability to continue as a going concern. Moreover, the Executive Committee has the responsibility for disclosing, as applicable, matters related to going concern. In addition, it is responsible for accounting based on the going concern accounting principle, unless actual or legal circumstances preclude this.

The Executive Committee is also responsible for the preparation of the management report, that as a whole provides a suitable view of the association's position and which is consistent with the annual financial statements in all significant respects, complies with German statutory regulations and suitably presenting the opportunities and risks of future development. The Executive Committee is furthermore responsible for the provisions and measures (systems) that it deems necessary to enable the preparation of a management report in accordance with the applicable German statutory regulations and to be able to provide sufficient appropriate evidence for the statements contained in the management report.

The Audit Committee is responsible for monitoring the association's accounting process of preparing the annual financial statements and the management report.

### **The auditor's responsibility for the audit of the annual financial statements and the management report**

It is our objective to obtain sufficient certainty whether the annual financial statements in its entirety are free from material misstatements, whether intentional or unintentional, and whether the management report as a whole provides a suitable view of the association's position and, in all significant respects, is consistent with the annual financial statements and the knowledge obtained in the audit, complies with the German legal requirements and adequately presents the opportunities and risks of future development, as well as to issue an auditor's report that includes our audit opinions on the annual financial statements and on the management report.

Sufficient certainty is a high level of certainty, but it is not a guarantee that an audit conducted in accordance with § 317 HGB and in compliance with German principles of proper auditing promulgated by the Institute of Public Auditors in Germany (IDW) will always detect a material misstatement. Misstatements can arise from infringements or inaccuracies and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual financial statements and this management report.

Throughout the audit, we exercise professional judgement and maintain a critical basic attitude. We also,

- identify and assess the risks of material misstatement, whether intentional or unintentional, in the annual financial statements and in the management report, plan and perform audit procedures responsive to those risks, and we gain audit evidence that is sufficient and appropriate to provide a basis for our audit opinions. The risk that material misstatements may not be exposed is greater in the event of infringements than in the event of inaccuracies, as infringements may involve collusion, forgery, intentional omissions, misrepresentation or the override of internal controls.
- gain an understanding of the internal control system relevant for the audit of the annual financial statements and the provisions and measures relevant for the audit of the management report in order to plan audit procedures that are appropriate in the given circumstances, but not for the purpose of expressing an audit opinion on the effectiveness of these systems of the association.
- evaluate the appropriateness of the accounting methods used by the Executive Committee and the justifiability of the estimates and related disclosures presented by the Executive Committee.



- conclude on the appropriateness of the Executive Committee's use of the going concern accounting principle and, based on the audit evidence obtained, whether material uncertainty exists related to events or circumstances that could raise significant doubts on the association's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in the auditor's report to the relevant disclosures in the annual financial statements and in the management report or, if such disclosures are inadequate, to modify our respective audit opinion. We draw our conclusions on the basis of the audit evidence obtained up to the date of our auditor's report. However, future events or circumstances may cause the association to cease to be able to continue as a going concern.
- evaluate the overall presentation, the structure and the content of the annual financial statements including the disclosures, and whether the annual financial statements present the underlying business transactions and events in a manner that the annual financial statements give a true and fair view of the net assets, financial position and results of operations of the association in accordance with German principles of proper accounting.
- evaluate the management report's consistency with the annual financial statements, its compliance with the German law, and the view of the association's position it provides.
- perform audit procedures on the forward-looking statements presented by the Executive Committee in the management report. On the basis of sufficient appropriate audit evidence we review, in particular, the significant assumptions used by the Executive Committee as a basis for the forward-looking statements, and evaluate the proper derivation of the forward-looking statements from these assumptions. We do not express a separate audit opinion on the forward-looking statements and on the underlying assumptions. There is a substantial unavoidable risk that future events will differ materially from the forward-looking statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in the internal control system that we identify during our audit.

Munich, 24 April 2020

**Deloitte GmbH**

Wirtschaftsprüfungsgesellschaft

Ralph Höll  
Wirtschaftsprüfer  
(German Public Auditor)

Sandro Süß  
Wirtschaftsprüfer  
(German Public Auditor)



